Susan Abushakra, MD
Founder, President and Senior Advisor
Susan was most recently a co-founder and Chief Medical Officer of Bonti Inc., a privately-held company that developed the first and only fast-acting botulinum neurotoxin for aesthetic and pain indications, that was acquired by Allergan in 2018 for $195 million. Susan has extensive experience in development of novel neurotoxins for various indications from her tenure at Allergan Pharmaceuticals and Bonti Inc. She is a board-certified neurologist with specialty and fellowship training at John Hopkins Medical Institutions, followed by more than 20 years of clinical and regulatory drug development roles in major pharmaceutical companies including Elan, Wyeth, and Astrazeneca. Her development experience included both early and late-stage development of migraine, pain and Alzheimer’s medicines. Susan is also the Chief Medical Officer of Alzheon Inc., a privately-held company developing treatments for Alzheimer’s and other diseases of aging.
Co-founder, C.E.O. and Chief Commercial Officer
Orlando has over 30 years of successful healthcare experience in marketing, sales, customer care, business development, fundraising and investor relations. He served as Commercial Lead at Bonti, an emerging biotech company developing a novel neurotoxin, which was acquired by Allergan in 2018 for $195 million. Previously served in senior leadership positions sparking aggressive revenue growth across numerous medical specialties in B2B and consumer-facing capacities in public and private companies, including Allergan, I-Flow Corporation, Biolase, Sonic Innovations and Alcon Laboratories.
Co-founder and Chief Scientific Officer
Mike has over 25 years of biotech and pharmaceutical experience in multiple therapeutic areas including devices, biologics, cell therapies, small molecules, and combination products. He was one of the founders of Bonti, a biotech company that developed a novel neurotoxin that was sold in 2018 to Allergan for $195 million. Previously served as Vice President Biologics Development at Allergan, leading product development activities for all biologics programs. Held various positions of increasing responsibility at Eisai, RenaMed, Cambridge Neuroscience, and Baxter. Education: University of Florida (Ph.D.)